Default header image

Minimal Residual Disease Detection in Canine Lymphoma

** Please note this study is no longer recruiting patients ** 


Canine multicentric B cell lymphoma generally responds well to chemotherapy. However, in the majority of cases the tumor recurs and the patient will eventually succumb to the disease. Currently, there are no reliable indicators that can predict if and when the disease will recur and what the overall survival will be. The goal of this study is to determine if the burden of remaining cancer during and after therapy can be used as a prognostic indicator.

Inclusion criteria:  

  • Dogs of any breed or age
  • A clinical diagnosis of multicentric, primary nodal B-cell lymphoma
  • No prior anti-tumour therapy
  • Scheduled for CHOP therapy at OVC 

Samples required:  

  • Fine needle aspirate of affected lymph node at initial visit
  • Blood sample (3mL) at:
    • 6 time points during treatment (scheduled visits)
    • after therapy – every 3 months & at relapse

Client Compensation:              

  • Immunophenotyping and clonality testing on the initial lymph node sample


  • Dr. Stefan Keller (PI)
  • Dr. Tony Mutsaers
  • Dr. Dorothee Bienzle
  • Dr. Olaf Berke
  • Dr. Nikos Darzentas


Vicky Sabine (PhD), Clinical Research Coordinator

Funded by OVC Pet Trust.

<Back to Closed & Completed Trials